Cover Image

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors

Show other versions (1)

Ertumaxomab (ertu) is a bispecific, trifunctional antibody targeting Her2/neu, CD3 and the Fcγ-receptors I, IIa, and III forming a tri-cell complex between tumor cell, T cell and accessory cells.

Saved in:
Bibliographic Details
Main Authors: Hänse, Nicole (Author) , Marmé, Frederik (Author) , Haag, Georg Martin (Author)
Format: Article (Journal)
Language:English
Published: 07 July 2016
In: BMC cancer
Year: 2016, Volume: 16
ISSN:1471-2407
DOI:10.1186/s12885-016-2449-0
Online Access:Verlag, Volltext: http://dx.doi.org/10.1186/s12885-016-2449-0
Verlag, Volltext: https://doi.org/10.1186/s12885-016-2449-0
Get full text
Author Notes:N. Haense, A. Atmaca, C. Pauligk, K. Steinmetz, F. Marmé, G.M. Haag, M. Rieger, O.G. Ottmann, P. Ruf, H. Lindhofer and S.-E. Al-Batran
Search Result 1
Cover Image

A phase I trial of the trifunctional anti Her2 × anti CD3 antibody ertumaxomab in patients with advanced solid tumors by Hänse, Nicole (Author) , Marmé, Frederik (Author) ,

BioMed Central; Springer 2016

Get full text
Article (Journal) Book/Monograph Online Resource

Saved in:
Show all versions (2)

Similar Items